Morusflavone, a New Therapeutic Candidate for Prostate Cancer by CYP17A1 Inhibition: Exhibited by Molecular Docking and Dynamics Simulation

Morusflavone, a New Therapeutic Candidate for Prostate Cancer by CYP17A1 Inhibition: Exhibited by Molecular Docking and Dynamics Simulation

Morusflavone, a flavonoid from <i>Morus alba</i> L., was evaluated for its interactive ability and stability with CYP17A1, in comparison with abiraterone, which is a Food and Drug Administration (FDA)-approved CYP17A1 inhibitor. CYP17A1 inhibition is an important therapeutic target for p...

Full description

Bibliographic Details
Main Authors: Sayed Aliul Hasan Abdi, Amena Ali, Shabihul Fatma Sayed, Mohamed Jawed Ahsan, Abu Tahir, Wasim Ahmad, Shatrunajay Shukla, Abuzer Ali
Format: Article
Language:English
Published: MDPI AG 2021-09-01
Series:Plants
Subjects:
Morusflavone
CYP17A1 inhibition
prostate cancer
molecular dynamics simulation
Online Access:https://www.mdpi.com/2223-7747/10/9/1912

Internet

https://www.mdpi.com/2223-7747/10/9/1912

Similar Items